462 results about "Determinant" patented technology

The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.

An automated system and method for determining the value of an intangible asset or intellectual property and developing a fair remuneration structure for licensing or purchasing the intangible asset or intellectual property by comparison to a dissected database of prior licensing and sale transactions. Valuation determinants and remuneration structures from prior transactions are extracted, analyzed and weighted and loaded into a knowledge base. Remuneration structures are normalized and used to train predictive algorithms based on a market analysis of previous transactions. The algorithms are able both to learn from previous transactions and to assess the importance of particular valuation determinants in determining the value under particular circumstances. An equitable rate for a new transaction is determined by examining the knowledge base and varying the valuation determinants. An optional expert system and dynamic modeling environment are provided.

Methods and compositions disclosed herein generally relates to methods of determining minimum hematopoietic stem cell (HSC) chimerism and gene dosage for correction of a hematopoietic disease; in particular, in in vivo models. The invention also relates to modified lentiviral expression vectors for increase a viral titer and various methods for increasing such titers as well as expression vectors capable of enhancing such titers. The invention also relates to CHS4 chromatin insulator-derived functional insulator sequences. The invention further relates to methods for genetic correction of diseases or reducing symptoms thereof, such as sickle cell anemia, a lysosomal storage disease. The invention further relates to a method of improving and/or correcting one or more central nervous system (CNS) abnormalities caused by one or more lysosomal storage disease. The invention further relates to methods of improving titer in transfection-based bioreactor culture production or transfection-based production systems using eukaryotic cells.

A select group, crowd-sourced enabled system, method and analytical structure to perform securities valuations and valuation adjustments thereof and generate derivatives therefrom is disclosed. The system is supplied with data generated by and from selected crowd-sourced entities. A computer retrieves and processes the data to perform an analysis according to a series of mapping points and criteria as a function of risk, asset class, issue name, coupons, maturity data, identification numbers, issuer data and other analytical determinants to generate a relative and absolute risk grade for each security. The system may then generate risk grades for baskets of securities and permit the establishment of derivatives (contracts) based upon an aggregate risk grade, which derivatives may be traded separate from the underlying securities.

The size and location of microsphere uptake/delivery are important determinants of the final biodistribution of oral microsphere systems. Formulations, kits, methods of administering the formulations, and using the kits are described herein. The formulations are oral dosage formulations. In one embodiment, the formulations contain microparticles and/or nanoparticles having a homogenous size range selected to optimize uptake in a specific region of the GI tract and target drug delivery to specific organs. In some embodiments, the dosage formulation contains an enteric coating and/or a magnetic material. In a preferred embodiment, the formulation contains a magnetic material and an active agent to be delivered, optionally the active agent is in the form of micro- or nano-particles. In some embodiments metallomucoadhesive materials and/or magnetic materials are employed as magnetic and/or mucoadhesive sources. Formulations containing magnetic materials can be localized using the kits and methods disclosed herein. In one embodiment, the method includes orally administering the formulation and applying an extracorporeal magnet to a site on the outside surface of the patient's body in an area that closely apposes the location in the gastrointestinal tract to which delivery of the formulation is desired. The extracorporeal magnet is applied for a suitable time period to allow for the drug to be released from the formulation and/or to allow for the formulation to adhere to the site. Both magnetic and mucoadhesive forces may be utilized to site-direct and retain the dosage form in the region of the gastrointestinal (GI) tract most suitable for the desired delivery.

A ground-fault detecting device includes a power source which is electrically insulated from a vehicle body, a pulse signal generator which generates a pulse signal having a high level and a low level which appear repeatedly in a prescribed cycle, a detection resistor which is connected to the pulse signal generator and the power source, a coupling capacitor which is connected to the detecting resistor in series, an integrator which integrates a difference between a first reference voltage and a detection voltage of the pulse signal at a connecting point of the detection resistor and the coupling capacitor over an integration interval, and a ground-fault determinant which judges whether a ground fault has occurred on the basis of an output of the integrator. The integration interval is at least part of a high-level interval and a low-level interval of the pulse signal.

An apparatus and method for inverting a 4×4 source matrix. A source matrix is divided into four 2×2 sub-matrices. A plurality of sub-matrix products are subsequently calculated from the sub-matrices. Next, a determinant of the source matrix is calculated to form a determinant residue utilizing the previously computed sub-matrix products. Calculation of partial inverse for each sub-matrix is next performed, using the sub-matrix products and determinants of the sub-matrices. Finally, an inverse of each sub-matrix is calculated, utilizing the partial inverse sub-matrices and the determinant residue to form an inverse of the 4×4 source matrix. The article allows processors to store two floating-point elements within a Single Instruction Multiple Data (SIMD) register. Accordingly, a sub-matrix is represented using two SIMD registers, resulting in improved computational locality and efficiency. Other embodiments are described and claimed.

Apparatus, systems, and methods of health reporting are disclosed that enhance decision support and provide alerts when health deterioration or the need for intervention has been detected. Embodiments utilize combined pictorial representations (including physical, mental, and social health determinants) as an avatar or pictogram, comparing health status to a general or target population, and using different methods to represent and reinforce health status. The apparatus, systems, and methods further enable individuals to access their own medical records in a way that can be understood by them and therefore is more widely accessible. The invention enhances health reporting, improving utility, usability and desirability of health reporting tools.

A continuous method for preparing proteosome-amphiphilic determinant vaccines for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiphilic determinants include lipopolysaccharides from gram negative bacteria, e.g. S. flexneri, P. shigelloides and S. sonnei. Proteosomes are obtained from group B type 2b meningococci. The active proteosome-amphiphilic determinant complexes (non-covalent complexes) of the vaccine are formed using diafiltration or ultrafiltration to remove the detergent under non-static conditions. The use of diafiltration or ultrafiltration decreases processing time and the opportunity for contamination and further permits the use of ambient temperature and efficient scale-up. In addition, the process permits the reliable and continuous monitoring of the dializate which enhances the efficiency of the entire process. The time of dialysis for the production of a lot of vaccine is reduced from 7-10 days to less than 72 hours and usually less than 48 or 24 hours. The use of the process optimizes the presence of each antigenic component in the preparation of multivalent vaccines.

The present invention leverages the invertibility of determinants of unimodular matrices to provide a universal hash function means with reversible properties and high speed performance. This provides, in one instance of the present invention, length controllable hash values comprised of vector pairs that can be processed as one instruction in a SIMD (single instruction, multiple data) equipped computational processor, where the vector pair is treated as a double word. The characteristics of the present invention permit its utilization in streaming cipher applications by providing key data to seed the ciphering process. Additionally, the present invention can utilize smaller key lengths than comparable mechanisms via inter-block chaining, can be utilized to double hash values via performing independent hash processes in parallel, and can be employed in applications, such as data integrity schemes, that require its unique processing characteristics.

A first display displays a predetermined number of symbols among a plurality of symbols including at least one special symbol. A storage stores a first number of times that a special symbol combination is appeared on the first display, the special symbol combination includes a first symbol combination in which at least one special symbol is included and a second symbol combination which is a predetermined combination of the symbols. A determinant determines whether the first number of times stored in the storage is not less than a second, predetermined number. A signal generator generates an award signal for causing the gaming machine to provide an award to a player in accordance with the special symbol combination displayed on the first display, when the determinant determines the first number of times is not less than the second number of times.

The invention relates to a method for quantitatively identifying relevant HLA-bound peptide antigens from primary tissue specimens on a large scale without labeling approaches. This method can not only be used for the development of peptide vaccines, but is also highly valuable for a molecularly defined immunomonitoring and the identification of new antigens for any immunotherapeutic strategy in which HLA-restricted antigenic determinants function as targets, such as a variety of subunit vaccines or adoptive T-cell transfer approaches in cancer, or infectious and autoimmune diseases.

The invention discloses a magnetic fluorescent kit for rapidly detecting microbes as well as a preparation method and a use method thereof. The kit comprises two components: 1) immunomagnetic microspheres specifically bound with the microbes to be detected; and 2) immunofluorescent microspheres specifically bound with the microbes to be detected. The preparation method comprises the following steps: (1) preparation of the immunomagnetic microspheres; and (2) preparation of the immunofluorescent microspheres. The use method comprises the following steps: (1) adding the sample to be detected, lyophilized powder of the immunomagnetic microspheres and the immunofluorescent microspheres to a buffer solution; (2) ensuring the surfaces of the identified microbes to have antigenic determinants simultaneously bound with the immunomagnetic microspheres and the immunofluorescent microspheres; (3) enriching the microbes bound with the immunomagnetic microspheres through magnetic separation of the immunomagnetic microspheres; and (4) qualitatively and quantitatively judging the microbes by measuring the fluorescence intensity of the immunofluorescent microspheres bound with the separated and enriched microbes. The kit, the preparation method and the use method have the advantages of rapidness, quantitative property and wide scope of application.

Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.

A method useful for the enumeration of cell populations in a biological sample includes the steps of reacting in a single reaction mixture a sample, a first antibody labeled with a fluorochrome having a first emission spectrum and an additional antibody. The first antibody binds to an antigenic determinant differentially expressed on leukocytes and non-leukocytes. The additional antibody binds to an antigenic determinant differentially expressed on mature and immature granulocytes or myeloid cells, and is labeled either with the first fluorochrome or an additional fluorochrome having an emission spectrum distinguishable from the first emission spectrum. The reaction mixture can be mixed with a nucleic acid dye having an emission spectrum that overlaps with one of the first or additional emission spectra. The reaction mixture may be treated with a lytic system that differentially lyses non-nucleated red blood cells and conserves leukocytes. Populations of hematological cells are detected and enumerated using at least two parameters (fluorescence, optical, and electrical) for each population.

Antibiotics (Abx) are the world's most misused drugs. Antibiotics misuse occurs when the drug is administered in case of a non-bacterial infection (such as a viral infection) for which it is ineffective. Overall, it is estimated that 40-70% of the worldwide Abx courses are mis-prescribed. The financial and health consequences of Abx over-prescription include the direct cost of the drugs, as well as the indirect costs of their side effects, which are estimated at >$15 billion annually. Furthermore, over-prescription directly causes the emergence of Abx-resistant strains of bacteria, which are recognized as one of the major threats to public health today. This generates an immediate need for reliable diagnostics to assist physicians in correct Abx prescription, especially at the point-of-care (POC) where most Abx are prescribed. Accordingly, some aspects of the present invention provide methods using biomarkers for rapidly detecting the source of infection and administrating the appropriate treatment.

Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome modified to encode a chimeric glycoprotein incorporating one or more heterologous antigenic domains, fragments, or epitopes of a second, antigenically distinct HPIV. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, and, optionally against respiratory syncytial virus (RSV). Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a HPIV vector genome or antigenome combined or integrated with one or more heterologous genome segment(s) encoding one or more antigenic determinant(s) of a heterologous PIV to encode a chimeric glycoprotein. In preferred aspects of the invention, the chimeric virus is attenuated for use as a vaccine agent by additional mutations or nucleotide modifications introduced into the chimeric genome or antigenome.

The singularity problem of the constant modulus algorithm (CMA) equalizer may be overcome by implementing the CMA equalizer as a two-stage equalizer, with the first stage being a modified version of a CMA equalizer and the second stage being a conventional CMA equalizer. The first stage may be made up of four sub-equalizers, of which only two of the sub-equalizers are independent, i.e., uncorrelated to each other. This first stage equalizer may compensate for PMD. The second stage equalizer is a conventional CMA equalizer made up of four sub-equalizers that are adjusted independently. This second stage equalizer may compensate for polarization-dependent loss (PDL) and any residual CD that is not fully compensated for by a CD compensator before the two-stage equalizer. Advantageously, as the determinant of the first stage never approaches zero, the singularity problem of a conventional CMA single-stage-only equalizer is avoided by the two-stage equalizer.